Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Converting Blood Cells into Therapeutic Approaches for Autoimmune Disease

By BiotechDaily International staff writers
Posted on 31 Jul 2013
Cells from one individual’s blood could be transformed into autoimmune diseases therapy, disorders such as rheumatoid arthritis and Crohn’s disease.

Chang Kim, a professor of comparative pathobiology at Purdue University (West Lafayette, IN, USA), has devised an application to direct the differentiation of T-cells. The technology employs naïve T-cells, immature cells from which all T-cells develop, and stimulates them to become suppressive T-cells that block the development of painful inflammation associated with autoimmune diseases.

Naïve T-cells can be collected from a patient’s blood, treated and then re-injected, according to Prof. Kim, who also is a university faculty scholar and member of Purdue’s Center for Cancer Research and Weldon School of Biomedical Engineering. “These cells are being directed to become a type of cell that is already present in our bodies, where a fine balance between inflammatory T-cells and suppressive T-cells is maintained,” he said. “We are just tipping the scales in favor of suppressive T-cells to reduce inflammation. Because of this there are none of the toxic side effects associated with many immune-suppressive drugs. In addition, cells from one's own body aren’t rejected and remain in the body much longer. Instead of taking a pill every day, this could lead to a treatment administered, for example, every six months.”

Autoimmune diseases occur when the immune system attacks one’s own body instead of fighting off infection from bacteria, viruses, and other foreign cells. An overactive immune system sends T-cells to healthy tissue and organs where they cause inflammation and tissue destruction.

Suppressive T-cells travel to regions of inflammation and inhibit the T-cells there without substantially reducing the number of T-cells in other areas of the body where they are needed for effective immune function, according to Dr. Kim. “Treatment with suppressive T-cells has the potential to be a much more precise and targeted regulation of immune function than what currently exists,” he said. “Treating autoimmune diseases without compromising a patient’s immune system has been a big problem in the field. We need to catch the thief without taking down the house, and this has that potential.”

Prof. Kim discovered that naïve T-cells cultured in the presence of the hormone progesterone can be induced to become suppressive T-cells. This project’s articles were published July 2013 in the Journal of Immunology and the European Journal of Immunology. The group also filed a patent based on this work.

Laboratory mice research showed that about 500,000 suppressive T-cells are needed to have an effect on inflammation, according to Prof. Kim. “More work needs to be done to determine the appropriate dosage of cells for a human patient, but the amount of blood many people regularly donate would likely yield multiple treatments,” he said.

In the next phase, Prof. Kim plans to explore at the molecular level how progesterone causes the cells to differentiate into suppressive T-cells and to discover the proteins and protein receptors involved. He stressed that a better determination of the molecular regulation of these cells could lead to a way to control their differentiation and function without using progesterone.

Related Links:

Purdue University




Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.